Intech Biopharm Corporation (TPEX:6461)

Intech Biopharm Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	173.68	16.8	198.65	77.73	64.82	220.48
Short-Term Investments	140	197.5	60	520	310	115
Cash & Short-Term Investments	313.68	214.3	258.65	597.73	374.82	335.48
Cash Growth	-1.93%	-17.15%	-56.73%	59.47%	11.73%	10.11%
Accounts Receivable	9.46	4.38	9.28	3.05	3.67	15.04
Other Receivables	4.78	2.59	9.83	8.7	7.94	7.94
Receivables	14.24	6.97	19.11	11.74	11.6	22.98
Inventory	115.13	116.48	63.86	41.53	51.82	59.87
Prepaid Expenses	75.77	65.38	68.65	43.62	40.7	33.74
Other Current Assets	0.14	-	0.06	0.41	0.13	4.26
Total Current Assets	518.97	403.13	410.32	695.02	479.06	456.33
Property, Plant & Equipment	1,381	1,403	1,885	1,900	2,009	2,090
Other Intangible Assets	10.77	4.89	3.86	4.88	4.8	4.62
Long-Term Deferred Tax Assets	24.77	24.77	24.77	24.77	24.77	24.77
Other Long-Term Assets	497.51	514.69	71.69	86.15	33.17	26.26
Total Assets	2,433	2,351	2,396	2,711	2,551	2,602

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	5.99	3.9	9.82	0.31	1.33	2.4
Accrued Expenses	-	26.44	28.82	19.24	23.71	20.82
Current Portion of Long-Term Debt	223.1	192.73	248.82	464.65	265.26	211.66
Current Portion of Leases	0.4	0.39	-	-	-	-
Current Unearned Revenue	12.94	12.94	81.18	78.54	78.31	78.99
Other Current Liabilities	37.58	6.92	18	5.99	5.23	9.35
Total Current Liabilities	280.01	243.32	386.64	568.73	373.82	323.22
Long-Term Debt	1,376	994.9	1,188	970.41	1,143	940.77
Long-Term Leases	0.31	0.6	-	-	-	-
Long-Term Unearned Revenue	15.14	8.84	5.53	2.35	-	-
Pension & Post-Retirement Benefits	-	0.85	-	-	-	-
Long-Term Deferred Tax Liabilities	0.02	0.02	-	-	-	-
Other Long-Term Liabilities	3.59	1.45	1.72	1.74	1.54	-
Total Liabilities	1,675	1,250	1,582	1,543	1,519	1,264

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	1,103	1,784	1,379	1,374	1,170	1,163
Additional Paid-In Capital	6.16	282.09	19.76	286.16	195.15	481.32
Retained Earnings	-351.35	-959.57	-579.76	-488.08	-327.88	-301.76
Comprehensive Income & Other	-0.28	-5.58	-5.16	-4.32	-5.13	-4.72
Shareholders' Equity	757.78	1,101	814.28	1,168	1,032	1,338
Total Liabilities & Equity	2,433	2,351	2,396	2,711	2,551	2,602

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	1,600	1,189	1,436	1,435	1,409	1,152
Net Cash (Debt)	-1,286	-974.31	-1,178	-837.33	-1,034	-816.94
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share	-11.95	-10.39	-13.87	-11.24	-14.39	-12.98
Filing Date Shares Outstanding	110.18	110.36	85.33	85	72.35	71.93
Total Common Shares Outstanding	110.18	110.36	85.33	85	72.35	71.93
Working Capital	238.95	159.81	23.68	126.3	105.24	133.11
Book Value Per Share	6.88	9.98	9.54	13.74	14.26	18.60
Tangible Book Value	747.01	1,096	810.42	1,163	1,027	1,333
Tangible Book Value Per Share	6.78	9.93	9.50	13.68	14.19	18.53
Land	-	516.45	919.87	919.87	950.72	950.72
Buildings	-	756.97	791.07	790.24	798.32	810.2
Machinery	-	754.83	724.87	657.12	645.9	633.52

Data Source: S&P Global Market Intelligence Last updated: Nov 11, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 12, 2026

Data Sources Report a data error